Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons

Journal of Infectious Diseases

Volumn 209, Issue 12, 2014, Pages 1929-1940

  Karmakar, Souvik ^a,b   Zhang, Weidong ^a,b   Ahmad, Gul ^c   Torben, Workineh ^d   Alam, Mayeen U ^a,b   Le, Loc ^a,b   Damian, Raymond T ^e   Wolf, Roman F ^f   White, Gary L ^f   Carey, David W ^f   Carter, Darrick ^g,h   Reed, Steven G ^g   Siddiqui, Afzal A ^a,b,i  

^a Center for Tropical Medicine and Infectious Diseases   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

^c PERU STATE COLLEGE   (United States)

^d TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^h PAI Life Sciences   (United States)

ⁱ Department of Internal Medicine ^*  (United States)

Author keywords

baboon; calpain; nonhuman primate; Schistosoma mansoni; Schistosomiasis; Sm p80; therapeutic vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; MESSENGER RNA; PROTEIN P80;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BABOON; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FECES ANALYSIS; FEMALE; FLOW CYTOMETRY; INFECTION PREVENTION; MALE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; SCHISTOSOMIASIS MANSONI; TRICHURIASIS; VACCINATION;

BABOON; CALPAIN; NONHUMAN PRIMATE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SM-P80; THERAPEUTIC VACCINE;

ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; B-LYMPHOCYTES; CALPAIN; DISEASE MODELS, ANIMAL; FECES; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MALE; PAPIO; PARASITE EGG COUNT; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; T-LYMPHOCYTES; VACCINATION; VACCINES;

EID: 84901757591     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu031     Document Type: Article

References (50)

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106-18. (Pubitemid 44402679)
2. Gryseels B. Schistosomiasis. Infect Dis Clin North Am 2012; 26:383-97.
3. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009; 3:e412.
4. Rollinson D, Knopp S, Levitz S, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop 2013; 128:423-40.
5. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002; 346:1212-20. (Pubitemid 34984584)
6. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. New vaccines for neglected parasitic diseases and dengue. Transl Res 2013; 162:144-55.
7. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113:95-104.
8. King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 2011; 5:e1321.
9. Lustigman S, Prichard RK, Gazzinelli A, et al. A research agenda for helminth diseases of humans: the problem of helminthiases. PLoS Negl Trop Dis 2012; 6:e1582.
10. Parker M, Allen T. Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Res Policy Syst 2011; 9:3.
11. Prichard RK, Basanez MG, Boatin BA, et al. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis 2012; 6:e1549.
12. Terer CC, Bustinduy AL, Magtanong RV, et al. Evaluation of the healthrelated quality of life of children in Schistosoma haematobium-endemic communities in Kenya: a cross-sectional study. PLoS Negl Trop Dis 2013; 7:e2106.
13. Karcz SR, Podesta RB, Siddiqui AA, Dekaban GA, Strejan GH, Clarke MW. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from Schistosoma mansoni. Mol Biochem Parasitol 1991; 49:333-6.
14. Siddiqui AA, Zhou Y, Podesta RB, et al. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1993; 1181:37-44. (Pubitemid 23087519)
15. Silva EE, Clarke MW, Podesta RB. Characterization of a C3 receptor on the envelope of Schistosoma mansoni. J Immunol 1993; 151:7057-66.
16. Ahmad G, Zhang W, Torben W, et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009; 105:1767-77.
17. Ahmad G, Zhang W, Torben W, et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009; 27:2830-7.
18. Ohta N, Kumagai T, Maruyama H, Yoshida A, He Y, Zhang R. Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol Int 2004; 53:175-81. (Pubitemid 38479892)
19. Siddiqui AA, Siddiqui BA, Ganley-Leal L. Schistosomiasis vaccines. Hum Vaccin 2011; 7:1192-7.
20. Zhang R, Yoshida A, Kumagai T, et al. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun 2001; 69:386-91. (Pubitemid 32038336)
21. ZhangW, Ahmad G, TorbenW, et al. Sm-p80-based DNAvaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 2010; 201:1105-12.
22. Long EG, Tsin AT, Robinson BA. Comparison of the FeKal CON-Trate system with the formalin-ethyl acetate technique for detection of intestinal parasites. J Clin Microbiol 1985; 22:210-1. (Pubitemid 15006955)
23. Ahmad G, TorbenW, ZhangW, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009; 31:156-61.
24. Ahmad G, Zhang W, Torben W, et al. Preclinical prophylactic efficacy testing of sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011; 204:1437-49.
25. Wilson RA, Langermans JA, Van Dam GJ, et al. Elimination of Schistosoma mansoni adult worms by rhesus macaques: basis for a therapeutic vaccine? PLoS Negl Trop Dis 2008; 2:e290.
26. Da'dara AA, Skelly PJ, Walker CM, Harn DA. A DNA-prime/proteinboost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection. Parasite Immunol 2003; 25:429-37. (Pubitemid 38058020)
27. Bickle QD, James ER. Resistance against Schistosoma mansoni induced by immunization of mice with cryopreserved schistosomula. Trans R Soc Trop Med Hyg 1978; 72:677-8. (Pubitemid 9065886)
28. Cook RM, Carvalho-Queiroz C, Wilding G, LoVerde PT. Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage. Infect Immun 2004; 72:6112-24. (Pubitemid 39303727)
29. El Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009; 27:666-73.
30. Pearson MS, Pickering DA, McSorley HJ, et al. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis 2012; 6:e1564.
31. Nyindo M, Farah IO. The baboon as a non-human primate model of human schistosome infection. Parasitol Today 1999; 15:478-82. (Pubitemid 29525604)
32. Siddiqui AA, Ahmad G, Damian RT, Kennedy RC. Experimental vaccines in animal models for schistosomiasis. Parasitol Res 2008; 102:825-33.
33. Damian RT, de la Rosa MA, Murfin DJ, Rawlings CA, Weina PJ, Xue YP. Further development of the baboon as a model for acute schistosomiasis. Mem Inst Oswaldo Cruz 1992; 87 (Suppl 4):261-9.
34. Kariuki TM, Farah IO. Resistance to re-infection after exposure to normal and attenuated schistosome parasites in the baboon model. Parasite Immunol 2005; 27:281-8. (Pubitemid 41344620)
35. Fairfax K, Nascimento M, Huang SC, Everts B, Pearce EJ. Th2 responses in schistosomiasis. Semin Immunopathol 2012; 34:863-71.
36. Schramm G, Haas H. Th2 immune response against Schistosoma mansoni infection. Microbes Infect 2010; 12:881-8.
37. Klementowicz JE, Travis MA, Grencis RK. Trichuris muris: a model of gastrointestinal parasite infection. Semin Immunopathol 2012; 34:815-28.
38. Kariuki TM, Van Dam GJ, Deelder AM, et al. Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine. Infect Immun 2006; 74:3979-86. (Pubitemid 43993330)
39. Garcia F, Leon A, Gatell JM, Plana M, Gallart T. Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012; 8:569-81.
40. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 2013; 119:421-75.
41. Prabowo SA, Groschel MI, Schmidt ED, et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202:95-104.
42. Valenta R, Campana R, Marth K, van Hage M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012; 272:144-57.
43. Zimmermann S, Dalpke A, Heeg K. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. Int J Med Microbiol 2008; 298:39-44. (Pubitemid 350216549)
44. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008; 21:659-67.
45. Doenhoff MJ, Hagan P, Cioli D, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009; 136:1825-35.
46. Wang W, Wang L, Liang YS. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 2012; 111:1871-7.
47. Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005; 21:112-7. (Pubitemid 40269774)
48. Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2:e244.
49. Bourke CD, Nausch N, Rujeni N, et al. Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis. J Infect Dis 2013; 208:159-69.
50. Soonawala D, Geerts JW, de Mos M, Yazdanbakhsh M, Visser LG. The immune response to schistosome antigens in formerly infected travelers. Am J Trop Med Hyg 2011; 84:43-7.